Concepts (73)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Diseases | 5 | 2017 | 122 | 1.750 |
Why?
|
| Physical Examination | 2 | 2017 | 152 | 1.110 |
Why?
|
| Dermatology | 2 | 2017 | 75 | 1.040 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 378 | 0.950 |
Why?
|
| Sarcoidosis | 3 | 2011 | 77 | 0.740 |
Why?
|
| Remote Consultation | 2 | 2017 | 50 | 0.710 |
Why?
|
| Dermatitis, Toxicodendron | 1 | 2018 | 2 | 0.680 |
Why?
|
| Hyperpigmentation | 1 | 2018 | 7 | 0.670 |
Why?
|
| Prednisone | 1 | 2018 | 104 | 0.660 |
Why?
|
| Telemedicine | 2 | 2017 | 699 | 0.650 |
Why?
|
| Rat-Bite Fever | 1 | 2017 | 1 | 0.620 |
Why?
|
| Purpura | 1 | 2017 | 7 | 0.610 |
Why?
|
| Blister | 1 | 2017 | 16 | 0.610 |
Why?
|
| Patients | 1 | 2017 | 69 | 0.580 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 234 | 0.580 |
Why?
|
| Skin | 1 | 2017 | 451 | 0.480 |
Why?
|
| Erythema Nodosum | 1 | 2010 | 1 | 0.380 |
Why?
|
| Keratinocytes | 2 | 2019 | 68 | 0.320 |
Why?
|
| Dermoscopy | 1 | 2005 | 14 | 0.270 |
Why?
|
| Nevus, Pigmented | 1 | 2005 | 30 | 0.260 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1139 | 0.250 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 375 | 0.240 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 4843 | 0.190 |
Why?
|
| Aged | 6 | 2019 | 14842 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 61 | 0.170 |
Why?
|
| Arm | 1 | 2018 | 59 | 0.170 |
Why?
|
| Foot | 1 | 2018 | 66 | 0.160 |
Why?
|
| Male | 8 | 2019 | 37281 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.150 |
Why?
|
| Humans | 11 | 2019 | 68525 | 0.150 |
Why?
|
| Keratoacanthoma | 1 | 2017 | 8 | 0.150 |
Why?
|
| Drug Eruptions | 1 | 2017 | 16 | 0.150 |
Why?
|
| Pemphigoid, Bullous | 1 | 2017 | 13 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 66 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 46 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 151 | 0.140 |
Why?
|
| Carcinoma | 1 | 2016 | 215 | 0.130 |
Why?
|
| Adolescent | 2 | 2018 | 8903 | 0.130 |
Why?
|
| Health Personnel | 1 | 2017 | 286 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 442 | 0.120 |
Why?
|
| Prognosis | 2 | 2010 | 2093 | 0.120 |
Why?
|
| Middle Aged | 5 | 2019 | 21119 | 0.110 |
Why?
|
| Adult | 4 | 2019 | 21375 | 0.100 |
Why?
|
| Interleukin-12 | 1 | 2011 | 75 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2011 | 101 | 0.100 |
Why?
|
| Infliximab | 1 | 2010 | 16 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2011 | 116 | 0.090 |
Why?
|
| Dermatologic Agents | 1 | 2010 | 32 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 498 | 0.090 |
Why?
|
| Female | 5 | 2019 | 38015 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2010 | 222 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 626 | 0.080 |
Why?
|
| Lupus Vulgaris | 1 | 2007 | 5 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 510 | 0.080 |
Why?
|
| Skin Ulcer | 1 | 2007 | 19 | 0.080 |
Why?
|
| Cicatrix | 1 | 2007 | 60 | 0.070 |
Why?
|
| Psoriasis | 1 | 2007 | 46 | 0.070 |
Why?
|
| Child | 1 | 2016 | 6400 | 0.070 |
Why?
|
| Young Adult | 1 | 2016 | 5708 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1548 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2007 | 1329 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2011 | 2688 | 0.050 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2019 | 40 | 0.040 |
Why?
|
| Risk Factors | 2 | 2019 | 5719 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 880 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 86 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 624 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 2004 | 0.030 |
Why?
|
| South Carolina | 1 | 2019 | 2750 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2011 | 63 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 86 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 209 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 682 | 0.020 |
Why?
|